Health Canada is informing Canadians and healthcare professionals about changes to the product labels of the Janssen and Vaxzevria (AstraZeneca) COVID-19 vaccines.The Department is updating the label of the Janssen COVID-19 Vaccine to provide additional information about the very rare risk of immune thrombocytopenia (ITP), an autoimmune condition, and the rare risk of venous thromboembolism...
Tag: astra zeneca
Post
Important Safety Information on AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Thrombosis with Thrombocytopenia – AstraZeneca Canada Inc. and Verity Pharmaceuticals Inc.
The AstraZeneca COVID-19 Vaccine and COVISHIELD were authorized for use in Canada on February 26, 2021, in accordance with the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Since the time of authorization, there have been very rare reports in Europe of thrombosis with thrombocytopenia following administration...
Post
Astra Zeneca/COVISHEILD COVID-19 Vaccine
On February 26, 2021, Health Canada authorized the use of the Astra Zeneca/COVISHELD vaccine. This vaccine is an adenovirus vector vaccine and is administered through two doses. More information about the AstraZeneca vaccine including how it works, how it’s given and possible side effects is available at https://www.canada.ca/en/health- canada/services/drugs-health-products/covid19- industry/drugs-vaccines- treatments/vaccines/astrazeneca.html HMC
Post
3 Approved COVID-19 Vaccines Efficacy
Interim results of two large randomized, placebo-controlled trials (RCTs) demonstrate ~95% relative efficacy in preventing COVID-19 (Pfizer, Moderna). The AstraZeneca/Oxford vaccine has ~70% relative efficacy. Absolute benefits will vary with baseline risk and time but if annual risk of developing COVID-19 is 20%, then vaccine would decrease risk to 1% (6% with AstraZeneca/Oxford). These vaccines...